Stock Taper 
NeuroPace, Inc. develops and sells the RNS system, a brain-responsive neuromodulation device for treating refractory focal epilepsy, enabling personalized real-time treatment, remote monitoring, and data recording for hospital use.
The RNS System is the first implantable, brain-responsive neurostimulation device that monitors and delivers personalized, real-time treatment for focal onset seizures in drug-resistant epilepsy patients.
NeuroPace announced it is terminating its distribution agreement for Stereo EEG (SEEG) products to strategically refocus its commercial and developmental resources entirely on its core, high-margin RNS System. This decision is intended to accelerate the adoption of the RNS System, establish it as the standard of care for drug-resistant epilepsy, and improve the company's overall gross margin.
NeuroPace (NASDAQ: NPCE - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings. Insider and Institutional Ownership 78.8% of NeuroPace shares are
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 DCTH | $15.50 | COMPARE |
 MASS | $12.45 | COMPARE |
 CERS | $2.35 | COMPARE |
 BWAY | $11.99 | COMPARE |
 SGHT | $8.59 | COMPARE |
 SENS | $9.93 | COMPARE |
 MOBI | $8.62 | COMPARE |
 RXST | $4.65 | COMPARE |
